Galera Therapeutics, Inc.

Lykos Therapeutics , still reeling from US Food and Drug Administration rejection of the company’s capsule formulation of the psychedelic drug midomafetamine for the treatment of post-traumatic stress

It’s understandable when a company running on fumes takes action to make its dwindling finances last while fundraising conditions are difficult. But when a company with a long cash runway implements l

Eiger BioPharmaceuticals, Inc. ’s peginterferon lambda, Gilead Sciences, Inc. ’s magrolimab, Takeda Pharmaceutical Co. Ltd. ’s TAK-994 and Bavarian Nordic A/S ’s RSV vaccine are the latest entrants

Having an approved and marketed drug is not enough to keep a biopharmaceutical company alive in the current financing environment in which stock prices are down and public offerings are not viable fun